Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Bariatric Surgery in Children. (BASIC)

25. August 2021 aktualisiert von: Maastricht University Medical Center

The BASIC Trial. Morbid Obesity in Children and Adolescents: a Prospective Randomised Trial of Conservative Treatment Versus Surgery

Rationale:

In the Western world overweight and obesity is an increasing problem both in adults and in children. In youth, it is associated with early death and a number of co-morbidities including metabolic and endocrine changes, increased inflammatory status, cardiovascular abnormalities, nonalcoholic fatty liver disease, and impaired quality of life.

The standard treatment for morbid obesity in children is by combined life style interventions. However, the medium and long term effects of dietetic interventions, behaviour therapy and medication is relatively poor. In adults bariatric surgery shows good results with up to 30% weight reduction in 3 years. The preliminary results in youth are similar, but surgery in this age group is relatively uncommon. In the Netherlands surgery in this age group is only allowed in clinical trials, until the benefits and risks have been established. (National Health Authorities)

Objective:

To determine if surgery gives a superior weight and body mass index (BMI) reduction than combined life style interventions in adolescents with morbid obesity and to assess its effect on obesity associated co-morbidity.

Study design:

Prospective randomised interventional study.

Study population:

Morbidly obese children, aged 14 - 16 years, with sex and age adjusted BMI >40 kg/m2 or >35 kg/m2 with co-morbidity.

Intervention:

Bariatric surgery by laparoscopic adjustable gastric band (LAGB) or combined life style interventions

Main study parameters/endpoints:

Primary endpoints: weight loss, loss of excess weight, loss of excess BMI. Secondary endpoints: Body composition, pubertal development, metabolic and endocrine changes, inflammatory status, cardiovascular abnormalities, non-alcoholic steatohepatitis, brain development, quality of life, and behaviour changes. The potential complications of surgery are monitored.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Tatsächlich)

60

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Limburg
      • Maastricht, Limburg, Niederlande, 6202ZA
        • Maastricht University Medical Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

14 Jahre bis 16 Jahre (Kind)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Aged 14 to 16
  • Age and sex adjusted BMI >40 kg/m2 or >35 kg/m2 with associated co-morbidity.

    * Associated co-morbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseudotumor cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-alcoholic steatohepatitis and dyslipidemia.

  • > 1 year multidisciplinary organized weight reducing attempts with less than 5% weight loss
  • Demonstrate decisional capacity

Exclusion Criteria:

  • Psychologically not suitable
  • Pre-menarche or bone age <15 years in boys
  • Obesity associated to other disorders such as hypothyroidism
  • Syndromal disorders such as Prader-Willi syndrome
  • Severe cardiorespiratory impairment (ASA class 3 or higher)
  • Insufficiently fluid in the Dutch language
  • Unwillingness to adhere to follow-up programmes

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Kontrollgruppe
Control group will receive standard therapy consisting of combined lifestyle interventions.
Experimental: Laparoscopic adjustable gastric band
Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
Control group will receive standard therapy consisting of combined lifestyle interventions.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Weight
Zeitfenster: 6 months
Weight loss, excess weight loss and loss of excess BMI.
6 months
Weight
Zeitfenster: 12 months
Weight loss, excess weight loss and loss of excess BMI.
12 months
Weight
Zeitfenster: 24 months
Weight loss, excess weight loss and loss of excess BMI.
24 months
Weight
Zeitfenster: 36 months
Weight loss, excess weight loss and loss of excess BMI.
36 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Body composition
Zeitfenster: 12 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
12 months
Pubertal development
Zeitfenster: 6 months
Follow-up of hormonal status and Tanner stages.
6 months
Metabolic and endocrine changes
Zeitfenster: 6 months
6 months
Inflammatory status
Zeitfenster: 6 months
Measurement of serum inflammatory markers.
6 months
Cardiovascular abnormalities
Zeitfenster: 6 months
6 months
Non-alcoholic fatty liver disease
Zeitfenster: 6 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
6 months
Quality of life changes
Zeitfenster: 6 months
6 months
Behaviour changes
Zeitfenster: 6 months
Measuring impulsivity and positive reward dominance with a computer task.
6 months
Operative complications
Zeitfenster: up to 36 months
Early and late complications are being monitored
up to 36 months
Effects on sleep architecture
Zeitfenster: 6 months
6 months
Brain development
Zeitfenster: 6 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
6 months
Body composition
Zeitfenster: 24 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
24 months
Body composition
Zeitfenster: 36 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
36 months
Pubertal development
Zeitfenster: 12 months
Follow-up of hormonal status and Tanner stages.
12 months
Pubertal development
Zeitfenster: 24 months
Follow-up of hormonal status and Tanner stages.
24 months
Pubertal development
Zeitfenster: 36 months
Follow-up of hormonal status and Tanner stages.
36 months
Metabolic and endocrine changes
Zeitfenster: 12 months
12 months
Metabolic and endocrine changes
Zeitfenster: 24 months
24 months
Metabolic and endocrine changes
Zeitfenster: 36 months
36 months
Inflammatory status
Zeitfenster: 12 months
Measurement of serum inflammatory markers.
12 months
Inflammatory status
Zeitfenster: 24 months
Measurement of serum inflammatory markers.
24 months
Inflammatory status
Zeitfenster: 36 months
Measurement of serum inflammatory markers.
36 months
Cardiovascular abnormalities
Zeitfenster: 12 months
12 months
Cardiovascular abnormalities
Zeitfenster: 24 months
24 months
Cardiovascular abnormalities
Zeitfenster: 36 months
36 months
Non-alcoholic fatty liver disease
Zeitfenster: 12 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
12 months
Non-alcoholic fatty liver disease
Zeitfenster: 24 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
24 months
Non-alcoholic fatty liver disease
Zeitfenster: 36 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
36 months
Quality of life changes
Zeitfenster: 12 months
12 months
Quality of life changes
Zeitfenster: 24 months
24 months
Quality of life changes
Zeitfenster: 36 months
36 months
Effects on sleep architecture
Zeitfenster: 12 months
12 months
Effects on sleep architecture
Zeitfenster: 24 months
24 months
Effects on sleep architecture
Zeitfenster: 36 months
36 months
Behaviour changes
Zeitfenster: 12 months
Measuring impulsivity and positive reward dominance with a computer task.
12 months
Behaviour changes
Zeitfenster: 24 months
Measuring impulsivity and positive reward dominance with a computer task.
24 months
Behaviour changes
Zeitfenster: 36 months
Measuring impulsivity and positive reward dominance with a computer task.
36 months
Brain development
Zeitfenster: 12 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
12 months
Brain development
Zeitfenster: 24 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
24 months
Brain development
Zeitfenster: 36 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
36 months
Physical activity
Zeitfenster: 6 months
Assessment of physical activity using a questionnaire and an accelerometer.
6 months
Physical activity
Zeitfenster: 12 months
Assessment of physical activity using a questionnaire and an accelerometer.
12 months
Physical activity
Zeitfenster: 24
Assessment of physical activity using a questionnaire and an accelerometer.
24
Physical activity
Zeitfenster: 36 months
Assessment of physical activity using a questionnaire and an accelerometer.
36 months
Behavior towards food
Zeitfenster: 6 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
6 months
Behavior towards food
Zeitfenster: 12 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
12 months
Behavior towards food
Zeitfenster: 24 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
24 months
Behavior towards food
Zeitfenster: 36 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
36 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: LWE van Heurn, Professor, Maastricht University Medical Center
  • Hauptermittler: Yvonne Roebroek, PhD Student, Maastricht University Medical Center
  • Hauptermittler: Givan F Paulus, PhD Student, Spaarne Gasthuis, Haarlem

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Dezember 2011

Primärer Abschluss (Voraussichtlich)

1. Dezember 2022

Studienabschluss (Voraussichtlich)

1. Dezember 2022

Studienanmeldedaten

Zuerst eingereicht

22. Juli 2010

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

29. Juli 2010

Zuerst gepostet (Schätzen)

30. Juli 2010

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

26. August 2021

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

25. August 2021

Zuletzt verifiziert

1. August 2021

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • NL26279.068.09

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Fettleibigkeit, krankhaft

Abonnieren